I just broadly wanted to understand what kind of traction we have been seeing in the European markets for Neoatricon, and going forward, what kind of growth can we expect from this product?
Secondly, on the Complex Hospital Generics business expanding into the rest of the world's market, you mentioned that you were trying not to be too aggressive with pricing on that front, but wanted to understand if you are going to be maintaining similar margin profiles to the product in the U.S. or what kind of margin profile can we expect from the rest of the world's market going forward?